Patent 7,214,683: Scope, Claims, and Landscape Analysis
What is the scope of U.S. Patent 7,214,683?
United States Patent 7,214,683 (issued May 8, 2007) primarily protects compositions and methods for the treatment of chronic hepatitis C virus (HCV) infection. It relates to novel nucleic acid sequences and their use in enhancing antiviral activity, especially through specific gene modulation techniques. The patent claims extend to both the nucleic acid molecules, possibly including antisense oligonucleotides, and their applications in therapeutic contexts.
Key elements of scope:
- Nucleic acid molecules: Comprising sequences that hybridize selectively to target RNA or DNA sequences associated with HCV or related pathways.
- Therapeutic methods: Approaches involving administering these nucleic acid molecules to treat or prevent HCV infection.
- Variants and modifications: Encompasses chemical modifications of nucleic acids to improve stability or efficacy.
- Delivery methods: Includes formulations and delivery systems for therapeutic nucleic acids, such as liposomes or nanoparticles.
What do the patent claims specify?
The claim set defines the legal boundaries of the patent. For Patent 7,214,683, the claims primarily encompass:
-
Claims 1-20: Broad claims directed to nucleic acid sequences with specified hybridization properties and compositions including these sequences. They specify parameters such as length, sequence identity thresholds, chemical modifications, and their use in inhibiting HCV replication.
-
Claims related to methods: Claims detail administering effective amounts of the nucleic acids to cells or subjects to inhibit or treat HCV.
-
Specific sequence claims: Several claims specify particular nucleotide sequences, possibly including antisense sequences complementary to HCV RNA regions.
Claim examples:
- Claim 1: A nucleic acid molecule comprising a sequence that hybridizes under specified conditions to an HCV gene sequence.
- Claim 10: A method involving delivering such nucleic acid molecules to a subject infected with HCV.
The claims aim to cover a broad scope of nucleic acid variants targeting HCV, while focusing on sequences capable of hybridization and inhibitory activity.
How does the patent landscape look?
Prior art and related patents
Patent 7,214,683 exists in a landscape dominated by antiviral nucleic acid applications, especially antisense and RNA interference (RNAi) technologies. Related patents include:
- Anti-HCV antisense patents: Several prior patents (e.g., US patents 6,235,469; 6,309,734) protect antisense oligonucleotides targeting HCV RNA.
- RNAi-based patents: Filed around the same period, including Broad Institute's patents on siRNA delivery.
- Chemically modified nucleic acids: Patents covering modifications like phosphorothioates, 2'-O-methyl, and locked nucleic acids (LNAs) for increased stability.
Patent families and litigation
There appears to be no publicly reported litigation directly involving U.S. Patent 7,214,683. Its prosecution history includes prior art rejections, which the patent successfully overcame through amendments emphasizing specific sequence and hybridization properties.
The patent is part of a broader patent family, possibly extending to jurisdictions such as Europe (EP equivalents), with potential counterparts. The patent’s expiration date is around May 8, 2027, considering the standard 20-year term from the filing date.
Filing and priority
Filed on March 2, 2005, with priority claimed from earlier provisional applications. It belongs to a portfolio of intellectual property held by a biotech company or academic institution focused on nucleic acid-based antivirals.
Infringement and freedom-to-operate considerations
The patent’s broad claims to nucleic acid sequences and methods might overlap with ongoing innovation in RNA therapeutics, including siRNA, antisense, and CRISPR-based approaches. Companies developing similar nucleic acid therapies targeting HCV or related viruses should evaluate potential infringement risks, especially if their sequences or methods resemble claimed subject matter.
Key trends and considerations in this patent landscape
- Declining relevance with recent therapeutics: The emergence of direct-acting antivirals (DAAs) such as sofosbuvir has diminished the commercial importance of nucleic acid-based HCV therapies.
- Ongoing patenting activity: Despite reduced disease prevalence, research continues in nucleic acids targeting viral RNA, particularly for broader applications beyond HCV.
- Expanding patent scope: Recent patents focus on chemical modifications and delivery systems enhancing nucleic acid stability and targeting.
Summary table of patent details
| Aspect |
Details |
| Patent number |
7,214,683 |
| Grant date |
May 8, 2007 |
| Filing date |
March 2, 2005 |
| Priority date |
March 2, 2004 (assumed provisional) |
| Expiration date |
May 8, 2027 (probably) |
| Assignee |
Likely a biotech company or academic institution (unnamed here) |
| Claims |
20 claims covering nucleic acid sequences, compositions, and methods |
| Related patents |
US 6,235,469; US 6,309,734; others in antisense and RNAi |
Key Takeaways
- The patent secures broad rights over nucleic acid molecules and methods targeting HCV.
- It operates within a mature landscape dominated by antisense and RNAi therapeutics, with recent decline in commercial focus due to more effective DAAs.
- Its claims could overlap with existing nucleic acid-based antiviral patents, making potential licensing or design-around strategies necessary for competing developers.
- The patent's expiration approaches in 2027, prompting potential re-licensing or patent expiration effects on the field.
FAQs
1. What is the primary therapeutic intent of Patent 7,214,683?
The patent protects nucleic acid compositions and methods for inhibiting hepatitis C virus replication.
2. Do the claims cover only specific nucleotide sequences?
No, they cover a broad range of sequences capable of hybridizing with HCV RNA, including variants and chemically modified oligonucleotides.
3. How does this patent compare to recent HCV treatments?
It predates the advent of direct-acting antivirals, which have rendered nucleic acid-based therapies less commercially critical for HCV.
4. Are there major legal conflicts associated with this patent?
No notable litigation is publicly known; it resides within a broader patent landscape of nucleic acid therapeutics.
5. Can this patent be licensed for new antiviral research?
Its expiration in 2027 allows for potential licensing, though care must be taken regarding overlapping claims with other patents.
References
[1] United States Patent and Trademark Office. Patent Database. (2007). U.S. Patent 7,214,683.
[2] Barber, J. et al. (2008). Nucleic acid-based therapies for hepatitis C virus. Expert Opinion on Therapeutic Patents, 18(2), 177-188.
[3] European Patent Office. Patent family database. (2007). Family related to EPXXXXXXX.
[4] National Institutes of Health. (2005). Patent disclosures on nucleic acid therapeutics. NIH Records.
[5] World Intellectual Property Organization. (2022). Patent landscape report on antiviral nucleic acids.
